Gen-Wealth Partners’s Gilead Sciences GILD Stock Holding History

Gen-Wealth Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.2K	Sell	159 -18	-10%	-$2.52K	0.01%	471
2025 Q4	$21.7K	Sell	177 -15	-8%	-$1.82K	0.01%	467
2025 Q3	$21.3K	Sell	192 -37	-16%	-$4.21K	0.01%	462
2025 Q2	$25.4K	Sell	229 -20	-8%	-$2.13K	0.01%	394
2025 Q1	$27.9K	Sell	249 -101	-29%	-$10.4K	0.01%	386
2024 Q4	$32.3K	Sell	350 -88	-20%	-$7.92K	0.01%	396
2024 Q3	$38.7K	Sell	438 -47	-10%	-$3.59K	0.02%	396
2024 Q2	$33.3K	Sell	485 -62	-11%	-$4.14K	0.02%	406
2024 Q1	$40.1K	Buy	+547	New	+$42.1K	0.02%	388

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Gen-Wealth Partners's GILD Position: Q1 2026 in Review

Gen-Wealth Partners reduced its Gilead Sciences (GILD) stake by 10% in Q1 2026, selling an estimated $2.52K and leaving 159 shares worth $22.2K. The position accounts for 0.01% of the portfolio, ranked #471.

Gen-Wealth Partners first reported a position in GILD in Q1 2024 and has held it in 9 quarters since. The position peaked at $40.1K in Q1 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Gen-Wealth Partners held 159 shares of Gilead Sciences worth $22.2K as of Q1 2026.
Gen-Wealth Partners sold 18 Gilead Sciences shares in Q1 2026, an estimated $2.52K.
Gilead Sciences made up 0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #471 holding.
Gen-Wealth Partners first reported a position in Gilead Sciences in Q1 2024 and has held it in 9 quarters since.
Gen-Wealth Partners's Gilead Sciences position peaked at $40.1K in Q1 2024.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.